These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 3226722

  • 1. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.
    Ali IU, Campbell G, Lidereau R, Callahan R.
    Oncogene Res; 1988 Sep; 3(2):139-46. PubMed ID: 3226722
    [Abstract] [Full Text] [Related]

  • 2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA.
    Cancer Res; 1991 Jan 15; 51(2):556-67. PubMed ID: 1670762
    [Abstract] [Full Text] [Related]

  • 3. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS, el-Naggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [Abstract] [Full Text] [Related]

  • 4. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
    Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE.
    Cancer Res; 1988 Mar 01; 48(5):1238-43. PubMed ID: 2893663
    [Abstract] [Full Text] [Related]

  • 5. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
    Zhou D, Battifora H, Yokota J, Yamamoto T, Cline MJ.
    Cancer Res; 1987 Nov 15; 47(22):6123-5. PubMed ID: 3664511
    [Abstract] [Full Text] [Related]

  • 6. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J.
    Cancer Res; 1989 Jun 01; 49(11):3104-8. PubMed ID: 2566377
    [Abstract] [Full Text] [Related]

  • 7. [Preliminary studies on c-erbB-2 protooncogene in breast cancer].
    He LW.
    Zhonghua Zhong Liu Za Zhi; 1992 May 01; 14(3):171-4. PubMed ID: 1356719
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M, Barrois M, Terrier MJ, Spielmann M, Riou G.
    Oncogene Res; 1988 May 01; 3(1):21-31. PubMed ID: 2905033
    [Abstract] [Full Text] [Related]

  • 9. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ, Frierson HF, Williams ME.
    Mod Pathol; 1993 Nov 01; 6(6):654-9. PubMed ID: 7905628
    [Abstract] [Full Text] [Related]

  • 10. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH, Bièche I, Hacène K, Lidereau R.
    Mod Pathol; 1994 Dec 01; 7(9):900-5. PubMed ID: 7892157
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
    Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P.
    Anticancer Res; 1994 Dec 01; 14(3B):1441-50. PubMed ID: 7915096
    [Abstract] [Full Text] [Related]

  • 12. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL.
    Clin Cancer Res; 1996 Jul 01; 2(7):1177-84. PubMed ID: 9816285
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
    Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA.
    Oncogene; 1987 Jul 01; 1(4):423-30. PubMed ID: 3330785
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The search for amplification of the ERBB-2 oncogene in human tumors].
    Imianitov EN, Chernitsa OI, Nikiforova IF, Titov KV, Khanson KP, Kniazev PG.
    Vopr Onkol; 1992 Jul 01; 38(6):652-9. PubMed ID: 1300765
    [Abstract] [Full Text] [Related]

  • 19. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG.
    Neoplasma; 1993 Jul 01; 40(1):35-9. PubMed ID: 7688867
    [Abstract] [Full Text] [Related]

  • 20. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.
    Singleton TP, Strickler JG.
    Pathol Annu; 1992 Jul 01; 27 Pt 1():165-90. PubMed ID: 1346551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.